- Home
- ANAB
ANAB
AnaptysBio Inc.
as 11-22-2024 4:00pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 600.4M | IPO Year: | 2017 |
| Target Price: | $54.64 | AVG Volume (30 days): | 623.5K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.36 - $41.31 | Next Earning Date: | 11-05-2024 |
| Revenue: | $57,172,000 | Revenue Growth: | 282.17% |
| Revenue Growth (this year): | 207.49% | Revenue Growth (next year): | -28.77% |
Stock Insider Trading Activity of AnaptysBio Inc. (ANAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lizzul Paul F. | ANAB | Chief Medical Officer | Sep 23 '24 | Sell | $38.67 | 1,500 | $58,005.00 | 15,398 | |
| Lizzul Paul F. | ANAB | Chief Medical Officer | Sep 14 '24 | Sell | $38.93 | 2,220 | $86,424.60 | 15,398 | |
| LOUMEAU ERIC J | ANAB | CHIEF LEGAL OFFICER | Sep 14 '24 | Sell | $39.16 | 12,500 | $492,460.53 | 8,520 | |
| MULROY DENNIS | ANAB | CHIEF FINANCIAL OFFICER | Sep 14 '24 | Sell | $39.53 | 12,220 | $487,724.60 | 4,744 |
Latest AnaptysBio Inc. News
ANAB Breaking Stock News: Dive into ANAB Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Zacks
16 days ago
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
16 days ago
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)
Simply Wall St.
18 days ago
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations
Zacks
19 days ago
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
19 days ago
Anaptys Announces Participation in November and December Investor Conferences
GlobeNewswire
19 days ago
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
MT Newswires
25 days ago
AnaptysBio Shares Fall After Eli Lilly Removes Arthritis Drug Peresolimab From Pipeline
Compare ANAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.